《吉林医学》杂志投稿注意事项

吉林医学2021年2月第42卷第2期• 481 •
carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma[J]•Gastroenterology^, 2010,138:493-502.
[32] Marrero JA,F en g Z,W ang Y,e t al.Alpha-fetoprotein,des -gamma carboxyprothrombin,and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma [J]. Gastroenterology, 2009, 137:110-118.
[33] Nakamura S,Nouso K,Sakaguchi K,et al.Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of pa­tients with hepatocellular carcinomas varies according to tumor size [J].Am J Gastroenterol,2006,101:2038-2043.
[34] Buti M,Gane E,Seto W K,et al.Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg- negative chronic hepatitis B virus infection：a ran-domised,double-blind,phase 3 ,non- inferiority trial[J].Lancet Gastroenterol Hepatol,2016,1 ：196-206.
[35] Chan H LY,Fung S,Seto W K,et al.Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of H BeAg- positive chronic hepatitis B virus infection：a randomised,double- blind,phase 3 ,non-inferiority trial[J].Lancet Gastroenterol Hep­atol2016,1：185-195.
[36] Wong G L,Chan H L,Tse Y K,et al.Normal on- treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B[J].J Hepatol, 2018,69:793-802.[37] Lilian Yan Liang,Grace Lai-H ung Wong.Unmet need in chronic hepatitis B management[J]. Clin Mol Hepatol,2019,25 (2) :172-180.
[38] Wong RJ,Ahm ed A,G ish RG.Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disor-ders[J].Clin Liver D is,2015,19:309-323.
[39] Sun W,Liu Y,Shou D,et al.AFP (alpha fetoprotein): ■w h o are you in gastrology? [J].Cancer Lett,2015,357(1):43- 46.
[40] Colombo M.Screening for cancer in viral hepatitis.Clin Liver D is,2001,5:109-122.
[41] Loglio A,Iavarone M,Vigano M,et al.Minimal increases of serum alpha- foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy[J].liver Int, 2019,39(10) :1964-1974.
[42] Chan AW,Wong GL,Chan H Y,et al.Concurrent fatty liv­er increases risk of hepatocellular carcinoma among patients with chronic hepatitis B[J].J Gastroenterol Hepatol,2017;32(3):667 -676.
[43] Wu S,Kong Y,P iao H,et al.On-treatment changes of liv­er stiffness at week 26 could predict 2 - year clinical outcomes in
H BV- related compensated cirrhosis[J] .J Liver Int,2018,38
(6) :1045-1054.
[收稿日期:2020-02-05编校:王丽娜]
《吉林医学》杂志投稿注意事项
一、近期网上出现多处以《吉林医学》名义征集稿件的信息，给作者带来许多疑惑，为此，敬告广大作者不轻信网上征稿信息，以免造成不必要的麻烦与经济损失。

遇到有关问题请及时与编辑部取得联系。

二、《吉林医学》杂志自2009年1月起审稿中采用了科技论文复制程度的查阅系统，能准确查得论文复其他已发表论文的比率，本刊对复制率过高的论文行一审淘汰制。

在此敬告作者在参考相关文献时，请勿将文
献内容原文大块转用，要结合作者第一手资料进行相关分析，合理引用文献。

三、《吉林医学》杂志的投稿、修稿及稿件咨询均在网上进行,编辑部通过电子信箱（E-mail)与作者联系作者投稿后继续关注电子信箱的相关通知，审稿结果可在官网查询。

收到编辑部修稿通知的作者请仔细阅读
修稿要求,按编辑部要求修回稿件及办理通知中的相关事情。

如果有特殊要求,请在信中提出或电话咨询。

四、《吉林医学》杂志地址：吉林省长春市建政路971号，邮政编码：130061，电话**************，E-m ************.com 。